"Omics" research, monetization of intellectual property and fragmentation of knowledge: can clinical epidemiology strengthen integrative research?

Journal of Clinical Epidemiology

Volumn 60, Issue 12, 2007, Pages 1220-1225

  Porta, Miquel ^a,b   Hernández Aguado, Ildefonso ^b,c   Lumbreras, Blanca ^b,c   Crous Bou, Marta ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Clinical epidemiology; Genomics; Methods; Proteomics; Relevance; Validity

Indexed keywords

ARTICLE; BIOMICS; BIOTECHNOLOGICAL PROCEDURES; CLINICAL RESEARCH; COMMERCIAL PHENOMENA; COMPUTER PROGRAM; GENOMICS; HUMAN; INTERNET; KNOWLEDGE; MARKETING; MEDICAL TECHNOLOGY; METABOLOMICS; METHODOLOGY; MONEY; PATENT; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; SEMICONDUCTOR; THINKING; VALIDATION PROCESS;

EID: 34548641313     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2007.06.010     Document Type: Note

References (40)

1. Gould S.J. The hedgehog, the fox, and the magister's pox. Mending and minding the misconceived gap between science and the humanities (2004), Vintage, London p. 103
2. Porta M., and Alvarez-Dardet C. Epidemiology: bridges over (and across) roaring levels. J Epidemiol Community Health 52 (1998) 605
3. Porta M. Epidemiologic coherence. Re: "Biologic plausibility in causal inference: current method and practice". Am J Epidemiol 150 (1999) 217-218
4. Porta M., and Álvarez-Dardet C. How is causal inference practised by the biological sciences?. J Epidemiol Community Health 54 (2000) 559-560
5. Porta M., Fernandez E., and Alguacil J. Semiology, proteomics and the early detection of symptomatic cancer. J Clin Epidemiol 56 (2003) 815-819
6. Bolúmar F., and Porta M. Epidemiologic methods: beyond clinical medicine, beyond epidemiology. Eur J Epidemiol 19 (2004) 733-735
7. Lumbreras B., Porta M., and Hernández-Aguado I. Assessing the social meaning, value and implications of research in genomics. [Editorial]. J Epidemiol Community Health 61 (2007) 755-756
8. Haynes R.B., Sackett D.L., Guyatt G.H., and Tugwell P. Clinical epidemiology. How to do clinical practice research. 3rd edition (2006), Lippincott, Williams & Wilkins, Philadelphia, PA
9. Fletcher R.H., and Fletcher S.W. Clinical epidemiology. The essentials. 4th edition (2005), Lippincott, Williams & Wilkins, Philadelphia, PA
10. Feinstein A.R. Clinical epidemiology: the architecture of clinical research (1985), W.B. Saunders, Philadelphia, PA
11. Zolg W. The proteomic search for diagnostic biomarkers: lost in translation?. Mol Cell Proteomics 5 (2006) 1720-1726
12. Silverthorne S. Science business: what happened to Biotech?. Interview to Gary Pisano. Harvard Business School newsletter "Working knowledge" (2006) 1-3. http://hbswk.hbs.edu/item/5503.html Accessed May 20, 2007. Available at
13. Porta M., Ayude D., Alguacil J., and Jariod M. Exploring environmental causes of altered ras effects: fragmentation plus integration?. Mol Carcinog 36 (2003) 45-52
14. Ransohoff D.F. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 97 (2005) 315-319
15. Ransohoff D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4 (2004) 309-314
16. Ransohoff D.F. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 5 (2005) 142-149
17. Ransohoff D.F. Evaluating discovery-based research: when biologic reasoning cannot work. Gastroenterology 127 (2004) 1028
18. Ransohoff D.F. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 60 (2007) 1205-1219
19. Vineis P., and Christiani D.C. Geneting testing for sale. Epidemiology 15 (2004) 3-5
20. Pollack A. New cancer test stirs hope and concern. N Y Times, 3 Feb 2004, pp. 1 and 6.
21. Armstrong D. Medical journal spikes article on industry ties of kidney group Wall St J. 26 Dec 2006, p. B1.
22. Hernández-Aguado I. The winding road towards evidence based diagnoses. J Epidemiol Community Health 56 (2002) 323-325
23. Bogardus Jr. S.T., Concato J., and Feinstein A.R. Clinical epidemiological quality in molecular genetic research: the need for methodological standards. JAMA 281 (1999) 1919-1926
24. Reid M.C., Lachs M.S., and Feinstein A.R. Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA 274 (1995) 645-651
25. Lijmer J.G., Mol B.W., Heisterkamp S., Bonsel G.J., Prins M.H., van der Meulen J.H., et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 282 (1999) 1061-1066
26. Ramos Rincón J.M., and Hernández-Aguado I. Research on diagnostic tests in Medicina Clinica. A methodological assessment. Med Clin (Barc) 111 (1998) 129-134
27. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. Standards for Reporting of Diagnostic Accuracy. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49 (2003) 7-18
28. Lumbreras B., Jarrin I., and Hernández-Aguado I. Evaluation of the research methodology in genetic, molecular and proteomic tests. Gac Sanit 20 (2006) 368-373
29. Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93 (2001) 1054-1061
30. Lumbreras-Lacarra B., Ramos-Rincon J.M., and Hernandez-Aguado I. Methodology in diagnostic laboratory test research in clinical chemistry and clinical chemistry and laboratory medicine. Clin Chem 50 (2004) 530-536
31. Tworoger S.S., and Hankinson S.E. Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis. Cancer Causes Control 17 (2006) 889-899
32. Porta M. Role of organochlorine compounds in the etiology of pancreatic cancer: a proposal to develop methodological standards. Epidemiology 12 (2001) 272-276
33. Porta M., Grimalt J.O., Jariod M., Ruiz L., Marco E., López T., et al. The influence of lipid and lifestyle factors upon correlations between highly prevalent organochlorine compounds in patients with exocrine pancreatic cancer. Environ Int 33 (2007) 946-954
34. Porta M., Pumarega J., Ferrer-Armengou O., López T., Alguacil J., Malats N., et al. Timing of blood extraction in epidemiologic and proteomic studies: results and proposals from the PANKRAS II Study. Eur J Epidemiol 22 (2007) 577-588
35. Porta M., Malats N., Corominas J.M., Rifa J., Pinol J.L., and Real F.X. Pankras I Project Investigators. Generalizing molecular results arising from incomplete biological samples: expected bias and unexpected findings. Ann Epidemiol 12 (2002) 7-14
36. Porta M., Malats N., Vioque J., Carrato C., Soler M., Ruiz L., et al. Incomplete overlapping of biological, clinical and environmental information in molecular epidemiologic studies: a variety of causes and a cascade of consequences. J Epidemiol Community Health 56 (2002) 734-738
37. Knottnerus J.A., and Muris J.W. Assessment of the accuracy of diagnostic tests: the cross-sectional study. J Clin Epidemiol 56 (2003) 1118-1128
38. Li D., Jiao L., and Porta M. Epidemiology. In: von Hoff D.D., Evans D.B., and Hruban R.H. (Eds). Pancreatic cancer (2005), Jones & Bartlett, Boston, MA 103-117
39. Porta M., Fabregat X., Malats N., Guarner L., Carrato A., de Miguel A., et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 7 (2005) 189-197
40. Porta M, Ferrer-Armengou O, Pumarega J, López T, Crous-Bou M, Alguacil A, et al. Exocrine pancreatic cancer clinical factors were related to timing of blood extraction and influenced serum concentrations of lipids. J Clin Epidemiol [in press].